How Genomic Testing and Targeted Therapies Are Shifting the Mindset for Treating Acute Myeloid Leukemia
Questions and answers with Dr. Eunice Wang, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, an unpaid Astellas consultant
Read More
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab